

LISTING OF CLAIMS

1. (previously presented) Liquid or pasty thixotropic compositions which contain a continuous dispersing phase, a dispersed phase and one or more active substances, intended for filling hard capsules at room temperature, wherein :

- their complex modulus G^* is greater than about 100 Pa,
- their phase shift δ is less than about 45° ,
- their viscosity decreases with increasing shear rate,
- under the effect of a constant shear rate γ_0 , the viscosity of the said compositions decreases in a delayed manner over time and stabilizes at the equilibrium value η_{eq} of between 10 mPa.s and about 10,000 mPa.s, when γ_0 is between 100 and 1000 s^{-1} and
- after making the said shear rate 0, the complex modulus and the phase shift of the said compositions resume, after a time t of less than 1 hour, G^* and δ values of greater than about 100 Pa and of less than about 45° , respectively,

and wherein the continuous phase consists of at least one vehicle selected from amphiphilic esters having an HLB between 3 and 15.

2. (previously presented) A composition according to Claim 1, wherein:

- G^* is greater than 1000 Pa, and/or
- δ is less than 25° and /or
- η_{eq} is between 100 and 1500 mPa.s when γ_0 is between 100 and 1000 s^{-1} and/or
- t is less than 30 min.

3. (previously deleted)

4. (previously deleted)

US Serial No. 09/743,248
PF84 PCTUS
September 25, 2003

(previously presented) A composition according to Claim 1, wherein the dispersed phase is selected from hydrophilic or hydrophobic pyrogenic silica particles and ethylene oxide/propylene oxide copolymers, the latter making it possible to achieve, when combined with the continuous phase, HLB values ranging up to about 20.

5. (previously presented) A composition according to Claim 1, wherein the active substance is liquid, pasty or solid.
6. (previously presented) A composition according to Claim 6, wherein the active substance is selected from milnacipran hydrochloride, baquimast, nifedipine, triamterene, aluminum hydroxychloride, sodium salicylate, vancomycin, paraneethadone and griseofulvin.
7. (previously presented) A composition according to Claim 1, wherein the dispersed phase of the preparations according to the invention represent 1 to 30% m/m of the preparation.
8. (previously presented) A composition according to Claim 8, wherein the dispersed phase of the dispersions according to the invention represent from 5 to 15% m/m of the preparation.
9. (previously presented) A composition according to Claim 1, wherein the hard capsules consist of gelatin or of any cellulose polymer capable of fulfilling the functions of the use of gelatin in the form of a hard capsule.
10. (previously presented) A composition according to Claim 1, wherein the hard capsules consist of hydroxypropylmethylcellulose.
11. ~~(newly added) A composition according to Claim 1, wherein the amphiphilic ester is a polyethylized glyceride.~~

US Serial No. 09/743,248
PF84 PCTUS
September 25, 2003